Shares of Arcturus Therapeutics (ARCT) have gained 7.5% over the past four weeks to close the last trading session at $12.81, ...

Fintel reports that on May 28, 2025, Scotiabank initiated coverage of Arcturus Therapeutics Holdings (NasdaqGM:ARCT) with a ...

Arcturus And The Struggle For Substantive Justice. Legal News and Analysis - India - Intellectual Property - Conventus Law ...

About Arcturus Therapeutics Holdings Inc. Arcturus Therapeutics Holdings, Inc. operates as a late-stage clinical mRNA medicines and vaccine company, which engages in the development of infectious ...

Overview of RNA Therapeutics MarketThe Global RNA Therapeutics Market is valued at USD 10.9 Billion in 2024 and is projected ...

The consensus price target hints at a 503.6% upside potential for Arcturus Therapeutics (ARCT). While empirical research shows that this sought-after metric is hardly effective, an upward trend in ...

During the last three months, 7 analysts shared their evaluations of Arcturus Therapeutics (NASDAQ:ARCT), revealing diverse outlooks from bullish to bearish. The following table summarizes their ...

Arcturus Therapeutics Holdings Inc. (ARCT) reported its first-quarter 2025 financial results, revealing a significant revenue shortfall and a net loss that missed analyst expectations. Despite the ...

SAN DIEGO, May 12, 2025--(BUSINESS WIRE)--Arcturus Therapeutics Holdings Inc. (the "Company", "Arcturus", Nasdaq: ARCT), a commercial messenger RNA medicines company focused on the development of ...